What is UroMems?
Founded in 2011 by Pr Pierre Mozer, Hamid Lamraoui, and Stéphane Lavallée, UroMems is dedicated to the design, development, and commercialization of active implantable medical devices. The company addresses critical unmet clinical needs, focusing on conditions that significantly impact patients' quality of life. UroMems' innovative approach positions it as a key player in the medtech sector, aiming to provide advanced solutions for prevalent and debilitating health issues.
How much funding has UroMems raised?
UroMems has raised a total of $149.1M across 4 funding rounds:
Grant
$2M
Series A
$12.9M
Series B
$27.2M
Series C
$47M
Grant (2016): $2M, investors not publicly disclosed
Series A (2016): $12.9M led by CEA Investissement, Wellington Partners, Cita Investissement, Bpifrance, and b-to-v Partners AG
Series B (2020): $27.2M supported by Banque Populaire, Hil-Invent, Supernova Invest, Crédit Agricole, Wellington Partners, Cita Investissement, Caisse d’Epargne, BNP Paribas, Bpifrance, btov Partners, and Financière Arbevel
Series C (2024): $47M featuring Supernova Invest, Bpifrance, and Crédit Mutuel Innovation
Key Investors in UroMems
Wellington Partners
Wellington Partners is a leading European venture capital firm specializing in early- and growth-stage life science companies, including medical devices and digital health. They support entrepreneurs in transforming innovative ideas into successful businesses.
Cita Investissement
CITA is an investment firm that partners with business leaders to support growth projects through minority investments, offering venture capital for young growth companies and development capital for established firms.
Supernova Invest
Supernova Invest provides expertise and patient capital to high-growth start-ups in Industrial Technologies, Digital, Healthcare, and Cleantech sectors, empowering deeptech leaders.
What's next for UroMems?
With the recent major strategic investment, UroMems is poised for accelerated growth and market expansion. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support broader commercialization efforts. The company's trajectory suggests a focus on scaling operations and solidifying its market presence, leveraging its innovative technology to address significant patient needs. Future developments will likely involve clinical validation and market penetration strategies.
See full UroMems company page
